Compare TBLA & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBLA | INDV |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 3.7B |
| IPO Year | N/A | 2014 |
| Metric | TBLA | INDV |
|---|---|---|
| Price | $3.21 | $30.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 1.9M | ★ 3.2M |
| Earning Date | 05-06-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 1.64 |
| Revenue | N/A | ★ $1,239,000,000.00 |
| Revenue This Year | $7.63 | N/A |
| Revenue Next Year | $5.25 | N/A |
| P/E Ratio | $42.36 | ★ $18.58 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $2.71 | $8.65 |
| 52 Week High | $4.65 | $38.00 |
| Indicator | TBLA | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 50.96 | 46.63 |
| Support Level | $3.16 | $29.71 |
| Resistance Level | $3.45 | $35.75 |
| Average True Range (ATR) | 0.09 | 1.31 |
| MACD | 0.03 | 0.14 |
| Stochastic Oscillator | 89.47 | 61.18 |
Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).